All posts by Molecular Innovations

Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study

The authors of the publication below utilized the active human PAI-1 functional assay ELISA kit from Molecular Innovations.

Biomarkers in cancer patients at risk for venous thromboembolism: data from the AVERT study

The mechanisms surrounding cancer-associated venous thromboembolism (VTE) are not well characterized. AVERT, a randomized placebo controlled thromboprophylaxis study in ambulatory cancer patients, provides a unique opportunity to gain insights into thrombotic mechanism(s).

“Among a cohort of ambulatory patients at intermediate to high risk of VTE, these exploratory findings suggest that baseline activation of coagulation and fibrinolysis pathways vary significantly by tumor type and disease stage.”

“Active PAI-1 in PFP (i.e., the fraction that is unbound to tPA or u-PA, and therefore retains full inhibitory capacity) was measured by ELISA (Molecular Innovations, Novi, MI, USA, cat. no. HPAIKT), according to the manufacturer’s specifications.”

“Patients with pancreatic cancer and metastasis to 2 or more sites had elevated levels of aPAI-1.”

Semen Extracellular Vesicles From HIV-1–Infected Individuals Inhibit HIV-1 Replication In Vitro, and Extracellular Vesicles Carry Antiretroviral Drugs In Vivo

Semen Extracellular Vesicles From HIV-1-Infected Individuals Inhibit HIV-1 Replication In Vitro, and Extracellular Vesicles Carry Antiretroviral Drugs In Vivo – PubMed

1 Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA. 2 Medical Service, Iowa City Veterans Affairs Medical Center, Iowa City, IA. 3 Department of Pharmacology, Stony Brook University School of Medicine, Stony Brook, NY. 4 Antiviral Pharmacology Laboratory, College of Pharmacy, UNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE.

ENHANCING PLASMIN ACTIVITY TO PREVENT SOFT TISSUE CALCIFICATION [Patent]

ENHANCING PLASMIN ACTIVITY TO PREVENT SOFT TISSUE CALCIFICATION – Vanderbilt University

This application claims the benefit of U.S. Provisional Application Ser. No. 62/309,821, filed Mar. 17, 2016, the entire disclosure of which is incorporated herein by this reference. This invention was made with government support under Grant Nos. 5T32 HL007751, 5T32 GM007628, 1R03AR065762-01A1, S10RR027631, and 3T32DK007061-4151 awarded by the National Institutes of Health.

Products used: Human Plasminogen ELISA Kit

Structures of full-length plasma kallikrein bound to highly specific inhibitors describe a new mode of targeted inhibition

[From Abstract:] Plasma kallikrein (pKal) is a serine protease responsible for cleaving high-molecular-weight kininogen to produce the pro-inflammatory peptide, bradykinin. Unregulated pKal activity can lead to hereditary angioedema (HAE) following excess bradykinin release. HAE attacks can lead to a compromised airway that can be life threatening. As there are limited agents for prophylaxis of HAE attacks, there is a high unmet need for a therapeutic agent for regulating pKal with a high degree of specificity… [continue reading]

Cited Products: Human Kallikrein, Equine Kallikrein, Human Factor XIIA, Human TPA

Full Citation: Partridge J, Choy R, Silva-Garcia A, et al. Structures of full-length plasma kallikrein bound to highly specific inhibitors describe a new mode of targeted inhibition. Journal of Structural Biology. In Press, Accepted Manuscript. Available Online 12 March 2019.